Needham & Company reiterates a 'Buy' on Vivus (VVUS); 2012 Preview - Qnexa and Avanafil FDA Decisions in April
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Vivus (NASDAQ: VVUS) price target of $15.00.
Needham analyst says, "Regulatory decisions are pending for both Qnexa (obesity; PDUFA Apr 17) and Avanafil (erectile dysfunction; PDUFA Apr 29). An FDA Advisory Committee is expected to review the narrow label Qnexa application on Feb 22 (contraindication for women of child bearing potential). We are favorably inclined towards approval of Qnexa with a restricted label, but more cautious around a possible expansion to a broad label in the future. Initial FORTRESS data, which assessed topiramate risk for birth defects, pointed to a mean increased risk of oral cleft as high as 5.4x. The FORTRESS findings are generally consistent with other similar analyses of topiramate, although do not represent an ideal scenario. We expect Avanafil to be approved by the FDA in April."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.06 yesterday.
Needham analyst says, "Regulatory decisions are pending for both Qnexa (obesity; PDUFA Apr 17) and Avanafil (erectile dysfunction; PDUFA Apr 29). An FDA Advisory Committee is expected to review the narrow label Qnexa application on Feb 22 (contraindication for women of child bearing potential). We are favorably inclined towards approval of Qnexa with a restricted label, but more cautious around a possible expansion to a broad label in the future. Initial FORTRESS data, which assessed topiramate risk for birth defects, pointed to a mean increased risk of oral cleft as high as 5.4x. The FORTRESS findings are generally consistent with other similar analyses of topiramate, although do not represent an ideal scenario. We expect Avanafil to be approved by the FDA in April."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Needham Reiterates Buy Rating on Digimarc (DMRC)
- Freedom Broker Upgrades Serve Robotics (SERV) to Buy
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
